These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 27247135)

  • 1. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis.
    Leong DP; Caron F; Hillis C; Duan A; Healey JS; Fraser G; Siegal D
    Blood; 2016 Jul; 128(1):138-40. PubMed ID: 27247135
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of adverse effects/toxicity of ibrutinib.
    Paydas S
    Crit Rev Oncol Hematol; 2019 Apr; 136():56-63. PubMed ID: 30878129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study.
    Reda G; Fattizzo B; Cassin R; Mattiello V; Tonella T; Giannarelli D; Massari F; Cortelezzi A
    J Hematol Oncol; 2018 Jun; 11(1):79. PubMed ID: 29891001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.
    McMullen JR; Boey EJ; Ooi JY; Seymour JF; Keating MJ; Tam CS
    Blood; 2014 Dec; 124(25):3829-30. PubMed ID: 25498454
    [No Abstract]   [Full Text] [Related]  

  • 6. Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.
    Caldeira D; Alves D; Costa J; Ferreira JJ; Pinto FJ
    PLoS One; 2019; 14(2):e0211228. PubMed ID: 30785921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Staphylococcus aureus meningitis in a patient with mantle cell lymphoma under treatment with ibrutinib.
    Diamantopoulos PT; Psichogiou M; Pantazatou A; Zervakis K; Rougala N; Giannakopoulou N; Daikos G; Viniou NA
    Ann Hematol; 2017 Jun; 96(6):1049-1050. PubMed ID: 28247056
    [No Abstract]   [Full Text] [Related]  

  • 8. Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
    Ali N; Malik F; Jafri SIM; Naglak M; Sundermeyer M; Pickens PV
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S53-S61. PubMed ID: 28760303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Tran PN; O'Brien S
    Expert Opin Drug Saf; 2017 Sep; 16(9):1079-1088. PubMed ID: 28627951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New approved indication for ibrutinib.
    Aschenbrenner DS
    Am J Nurs; 2014 Jun; 114(6):21. PubMed ID: 24869579
    [No Abstract]   [Full Text] [Related]  

  • 11. Risk factors for the development of atrial fibrillation on ibrutinib treatment.
    Lentz R; Feinglass J; Ma S; Akhter N
    Leuk Lymphoma; 2019 Jun; 60(6):1447-1453. PubMed ID: 30730240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib promising in subtype of DLBCL.
    Brower V
    Lancet Oncol; 2015 Sep; 16(9):e428. PubMed ID: 26212869
    [No Abstract]   [Full Text] [Related]  

  • 13. B-cell receptor inhibitors in chronic lymphocytic leukemia.
    Flinn IW
    Clin Adv Hematol Oncol; 2011 Aug; 9(8):605-6. PubMed ID: 22236988
    [No Abstract]   [Full Text] [Related]  

  • 14. Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias.
    Fabbro SK; Smith SM; Dubovsky JA; Gru AA; Jones JA
    JAMA Oncol; 2015 Aug; 1(5):684-6. PubMed ID: 26182170
    [No Abstract]   [Full Text] [Related]  

  • 15. Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies.
    Guha A; Derbala MH; Zhao Q; Wiczer TE; Woyach JA; Byrd JC; Awan FT; Addison D
    J Am Coll Cardiol; 2018 Aug; 72(6):697-698. PubMed ID: 30072003
    [No Abstract]   [Full Text] [Related]  

  • 16. Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies.
    Tillman BF; Pauff JM; Satyanarayana G; Talbott M; Warner JL
    Eur J Haematol; 2018 Apr; 100(4):325-334. PubMed ID: 29285806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
    Thorp BC; Badoux X
    Leuk Lymphoma; 2018 Feb; 59(2):311-320. PubMed ID: 28629235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ibrutinib: A new drug of B-cell malignancies].
    Thieblemont C
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
    Brown JR; Moslehi J; O'Brien S; Ghia P; Hillmen P; Cymbalista F; Shanafelt TD; Fraser G; Rule S; Kipps TJ; Coutre S; Dilhuydy MS; Cramer P; Tedeschi A; Jaeger U; Dreyling M; Byrd JC; Howes A; Todd M; Vermeulen J; James DF; Clow F; Styles L; Valentino R; Wildgust M; Mahler M; Burger JA
    Haematologica; 2017 Oct; 102(10):1796-1805. PubMed ID: 28751558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targets for Ibrutinib Beyond B Cell Malignancies.
    Berglöf A; Hamasy A; Meinke S; Palma M; Krstic A; Månsson R; Kimby E; Österborg A; Smith CI
    Scand J Immunol; 2015 Sep; 82(3):208-17. PubMed ID: 26111359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.